Disseminated superficial actinic porokeratosis (DSAP) L56.5 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM L56.5 became effective on October 1, 2018. This is the American ICD-10-CM version of L56.5 - other international versions of ICD-10 L56.5 may differ.
Porokeratosis typically doesn’t require treatment. In benign cases, your doctor will monitor the lesions and watch for signs of malignancy. In some cases, your doctor may prescribe topical or systemic drugs to help reduce your symptoms. There’s also evidence that laser treatments have improved the appearance of porokeratosis.
If you have a small, scaly patch of skin with a ridge-like border, it may be a form of porokeratosis. Your doctor or dermatologist can help with identification.
Different types include porokeratosis of Mibelli, linear porokeratosis and disseminated superficial actinic porokeratosis (DSAP). Manifests as a well-defined, slightly raised rim (made up of a cellular protein-keratin). The center may be scaly or thin. They grow gradually to between 3-10 mm, but grouped lesions will appear larger.
Disseminated superficial actinic porokeratosis, or DSAP, is an inherited keratinisation disorder that causes discrete dry patches on the arms and legs. DSAP is a special type of inherited 'sunspot". The name porokeratosis means scaly pore and is a misnomer as porokeratosis is not related to pores.
Summary. Disseminated superficial actinic porokeratosis (DSAP) is a skin condition that causes dry, scaly patches. Symptoms include a large number of small, brownish patches with a distinctive border, found most commonly on sun-exposed areas of the skin (particularly the lower arms and legs).
Background. Disseminated superficial actinic porokeratosis (DSAP) is a precancerous skin condition often seen by dermatologists that is characterised by multiple annular hyperkeratotic lesions on sun-exposed areas.
Actinic keratoses can be removed by freezing them with liquid nitrogen. Your doctor applies the substance to the affected skin, which causes blistering or peeling. As your skin heals, the damaged cells slough off, allowing new skin to appear. Cryotherapy is the most common treatment.
The development of disseminated superficial porokeratosis is occasionally observed in association with renal transplant, autoimmune diseases and various hematological disorders, suggesting a certain immunosuppression may trigger a widespread abnormal keratinization.
This patch grows in size, and the bumps may become raised with a ring around the outside of each spot. The exact cause of porokeratosis is not known, but genetic factors and having a weak immune system may put you at a greater risk for the condition. Sunlight, UV rays, and other radiation worsen the condition.
It is sometimes confused with actinic keratosis which is also caused by sun exposure (See Patient Information Leaflet on Actinic Keratoses); however, actinic keratosis is more likely to arise on the face and hands. DSAP is twice as likely to develop in women compared with men and is more common in lighter skin type.
Disease definition. A rare genetic disease which is a rare form of porokeratosis occurring mainly in adolescence and characterized by small pruritic or painful keratotic papules that first appear on the palms and soles, and may gradually spread to other body zones.
Punctate porokeratosis is a skin condition that appears in adulthood as many, tiny, ridgelike bumps on the palms of the hands and soles of the feet. These bumps may slowly spread over the skin and usually do not cause symptoms, though they sometimes cause itching or discomfort while walking.
ICD-10 code L57. 0 for Actinic keratosis is a medical classification as listed by WHO under the range - Diseases of the skin and subcutaneous tissue .
Fluorouracil has been the traditional topical treatment for actinic keratoses, although imiquimod 5% cream and diclofenac 3% gel are effective alternative therapies. There are too few controlled trials comparing treatment modalities for physicians to make sound, evidence-based treatment decisions.
The main difference between SCC in situ and AK is that in SCC in situ, the full thickness of the epidermis is involved with atypical proliferation of keratinocytes; whereas, in AK, the atypia is limited to lower levels of the epidermis and not its full thickness.
Porokeratosis. Medically reviewed by The Dermatologists and written by Dr. Alexander Börve. Porokeratosis (01) arm [ICD-10 L56.5] Porokeratosis is a skin condition involving lesions with thin center surrounded by raised ridges. It may be caused by genetics, UV rays or immunosuppression. Some lesions can develop into malignant carcinomas.
The lesion can grow up to 20cm in size into a giant porokeratosis. These lesions may arise in childhood, and have a later onset of sporadic lesions, which are most common on the limbs, especially the limbs, but can affect any body site. This condition usually presents at birth or in childhood.
There is no known cure for DSAP and porokeratosis of Mibelli, but creams such as topical retinoids, 5-fluorouracil and imiquimod offer some slight help. And cryosurgery is generally useful, but may lead to hyperpigmentation. American Osteopathic College of Dermatology. Porokeratosis of Mibelli.
All types of porokeratosis except PP come with a risk of developing a cancerous growth in a lesion, usually a squamous cell carcinoma.
If you notice any change in color or size, see your doctor. The most important way to prevent porokeratosis from worsening or becoming malignant is to protect yourself from UV rays.
Porokeratosis typically doesn’t require treatment. In benign cases, your doctor will monitor the lesions and watch for signs of malignancy. In some cases, your doctor may prescribe topical or systemic drugs to help reduce your symptoms.
Commonality: This subtype is rare. Age of onset: It typically develops during adulthood. Risk by gender: There isn’t a clear indicator that men or women are more at risk. Triggers: You may develop this subtype if you’re already affected by another form of porokeratosis.
Your individual risk is determined by your: Genes. If you have a parent with porokeratosis, you may inherit the damaged gene linked to the disease and develop the same type of porokeratosis.
There’s no magic bullet for improving porokeratosis lesions in the short term. Talk with your doctor about what treatment options are available and how they may fit into your lifestyle. Over the years, your porokeratosis may expand to cover more of your skin.